Treosulfan-based Conditioning for Transplantation in AML/MDS

Mise à jour : Il y a 4 ans
Référence : NCT00491634

Femme et Homme

  • | Pays :
  • Israel
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The study hypotheses is that the introduction of dose escalated treosulfan, in substitution to busulfan, will reduce toxicity after allogeneic transplantation while improving myeloablation and and disease control in patients with AML and MDS not eligible for standard transplantation.


Critère d'inclusion

  • Acute Myeloid Leukemia ,myelodysplastic syndrome

Liens